SEC Form 3 · accession 0001213900-26-098841
Actinium Pharmaceuticals, Inc. · ATNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adeela Kamal
Officer — Chief Scientific Officer
Period of report
Sep 3, 2026
Accepted (ET)
Sep 10, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001388320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 213,648 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.00 | holding | — | — | — | — | Sep 2, 2036 | Common Stock | 120,000 | — | D |
Explanation of responses
- F1Represents restricted stock units ("RSUs"). 80,000 of the RSUs vest as follows: 1/3 on September 2, 2027, 1/3 on September 2, 2028, and 1/3 on September 2, 2029. 133,648 of the RSUs vest on September 2, 2029.
- F2The stock options vest and become exercisable in fifty equal monthly tranches beginning on October 2, 2026.